Karyopharm Therapeutics Inc Sustainability Reports
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Its primary marketed product is XPOVIO (selinexor).
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300J1VANRCNTYST87
FIGI: BBG001V0G6X5
14 reports from 2013 to 2025
